

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b>  (Only for new nonprovisional applications under 37 CFR 1.53(b))	Attorney Docket No.	A013 US CON
	First Inventor	Browning, Jeffrey L. et al.
	Title	Soluble Lymphotoxin-Beta Receptors and
	Express Mail Label No.	EL543620827US

<b>APPLICATION ELEMENTS</b>  See MPEP chapter 600 concerning utility patent application contents.	<b>ADDRESS TO:</b> Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
---	---

<div>1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original and a duplicate for fee processing)</i></div> <div>2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.</div> <div>3. <input checked="" type="checkbox"/> Specification [Total Pages 70] <i>(preferred arrangement set forth below)</i><ul style="list-style-type: none"><li>- Descriptive title of the invention</li><li>- Cross Reference to Related Applications</li><li>- Statement Regarding Fed sponsored R &amp; D</li><li>- Reference to sequence listing, a table, or a computer program listing appendix</li><li>- Background of the Invention</li><li>- Brief Summary of the Invention</li><li>- Brief Description of the Drawings (if filed)</li><li>- Detailed Description</li><li>- Claim(s)</li><li>- Abstract of the Disclosure</li></ul></div> <div>4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [ Total Sheets ]</div> <div>5. Oath or Declaration [ Total Pages ]<div><div>a. <input type="checkbox"/> Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d))</div><div>b. <input checked="" type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)</div></div></div> <div>6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</div>	<div>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)</div> <div>8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)<div>a. <input checked="" type="checkbox"/> Computer Readable Form (CRF)</div><div>b. Specification Sequence Listing on:<div>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</div><div>ii. <input checked="" type="checkbox"/> paper</div></div><div>c. <input checked="" type="checkbox"/> Statements verifying identity of above copies</div></div>
--	---

<b>ACCOMPANYING APPLICATION PARTS</b>	
9. <input checked="" type="checkbox"/> Assignment Papers (cover sheet & document(s))	
10. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee)	<input checked="" type="checkbox"/> Power of Attorney
11. <input type="checkbox"/> English Translation Document (if applicable)	
12. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449	<input type="checkbox"/> Copies of IDS Citations
13. <input checked="" type="checkbox"/> Preliminary Amendment	
14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)	
15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)	
16. <input type="checkbox"/> Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.	
17. <input checked="" type="checkbox"/> Other: Comm. re: calculation of claims...	

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

<input checked="" type="checkbox"/> Continuation	<input type="checkbox"/> Divisional	<input type="checkbox"/> Continuation-in-part (CIP)	of prior application No.: 09/299,139
Prior application information Examiner F. Vander Vegt			Group Art Unit 1644

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

<b>19. CORRESPONDENCE ADDRESS</b>					
<input type="checkbox"/> Customer Number or Bar Code Label			or <input checked="" type="checkbox"/> Correspondence address below		
(insert Customer No. or Attach bar code label here)					
Name	Niki D. Cox, Esq.				
Address	BIOGEN, INC.				
	14 Cambridge Center				
City	Cambridge	State	MA	Zip Code	02142
Country	USA	Telephone	(617) 679-2079	Fax	(617) 679-2838

Name (Print/Type)	Niki D. Cox	Registration No. (Attorney/Agent)	42,446
Signature	<i>Niki D. Cox</i>	Date	10-31-01

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$) 740

## Complete if Known

Application Number	Continuation of 09/299,139
Filing Date	HEREWITH
First Named Inventor	Browning, Jeffrey L. et al.
Examiner Name	G. Bansal
Group Art Unit	1642
Attorney Docket No.	A013 US CON

## METHOD OF PAYMENT

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to

Deposit Account Number 02-2327  
Deposit Account Name

☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

☐ Applicant claims small entity status See 37 CFR 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit card ☐ Money Order ☐ Other

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
101 740	201 370	Utility filing fee	740
106 330	206 165	Design filing fee	
107 510	207 255	Plant filing fee	
108 740	208 370	Reissue filing fee	
114 160	214 80	Provisional filing fee	

SUBTOTAL (1) (\$) 740

### 2. EXTRA CLAIM FEES

Total Claims 1 -20\*\* = 0 X Fee from below = 0  
Independent Claims 1 -3\*\* = 0 X Fee Paid = 0  
Multiple Dependent = 0

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
103 18	203 9	Claims in excess of 20
102 84	202 42	Independent claims in excess of 3
104 280	204 140	Multiple dependent claim, if not paid
109 84	209 42	** Reissue independent claims over original patent
110 18	210 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES


Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105 130	205 65	Surcharge - late filing fee or oath	
127 50	227 25	Surcharge - late provisional filing fee or cover sheet	
139 130	139 130	Non-English specification	
147 2,520	147 2,520	For filing a request for ex parte reexamination	
112 920*	112 920*	Requesting publication of SIR prior to Examiner action	
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	
115 110	215 55	Extension for reply within first month	
116 400	216 200	Extension for reply within second month	
117 920	217 460	Extension for reply within third month	
118 1,440	218 720	Extension for reply within fourth month	
128 1,960	228 980	Extension for reply within fifth month	
119 320	219 160	Notice of Appeal	
120 320	220 160	Filing a brief in support of an appeal	
121 280	221 140	Request for oral hearing	
138 1,510	138 1,510	Petition to institute a public use proceeding	
140 110	240 55	Petition to revive - unavoidable	
141 1,280	241 640	Petition to revive - unintentional	
142 1,280	242 640	Utility issue fee (or reissue)	
143 460	243 230	Design issue fee	
144 620	244 310	Plant issue fee	
122 130	122 130	Petitions to the Commissioner	
123 50	123 50	Processing fee under 37 CFR 1.17(q)	
126 180	126 180	Submission of Information Disclosure Stmt	
581 40	581 40	Recording each patent assignment per property (times number of properties)	
146 740	246 370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149 740	249 370	For each additional invention to be examined (37 CFR § 1.129(b))	
179 740	279 370	Request for Continued Examination (RCE)	
169 900	169 900	Request for expedited examination of a design application	

Other fee (specify) \_\_\_\_\_

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 0

## SUBMITTED BY


Name (Print/Type)	Niki D. Cox, Esq.	Registration No. (Attorney/Agent)	42,446	Telephone	(617) 679-2079
Signature		Date	10-31-01		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

## CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service under 37 CFR 1.10 as Express Mail Label No. EL543620827US in an envelope addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231 on this 31<sup>st</sup> day of October, 2001.



Patricia Hofstetter

A013 US CON/NDC/jss

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: Browning et al.

Examiner: Unassigned

Filing Date: On even date herewith

Group Art Unit: Unassigned

Serial No.: Unassigned

For: Soluble Lymphotoxin-Beta Receptors And Anti-Lymphotoxin Receptor And  
Ligand Antibodies As Therapeutic Agents For The Treatment Of Immunological  
Diseases

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express mail, under Express mail No. EL543620827US to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231, on:

31 October 2001  
Date

Patricia Hofstetter  
Patricia Hofstetter

Communication

Box Patent Application  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Please cancel in this application original claims 2-50 of the prior application before calculating the filing fee. (At least one original independent claim has been retained for filing purposes.)

A Preliminary Amendment is being filed concurrently with this application. Claims added by the Preliminary Amendment have been properly numbered consecutively beginning with the number next following the highest number of **original** claims in the prior application.

Respectfully submitted,

Date: 10-31-01

Niki Cox  
Niki Cox, Esq. Reg. No. 42,446

BIOGEN, INC.  
14 Cambridge Center  
Cambridge, MA 02142  
(617) 679-2079 (Direct)  
(617) 679-2838 (Facsimile)

IN THE UNITED STATES RECEIVING OFFICE

In re application of: Browning, J. L. et al. U.S. Serial No.: Unassigned

U.S. Filing date: Herewith Group Art Unit: Unassigned

Continuation of  
Serial No.: 09/299,139 (Examiner G. Bansal, Group Art Unit 1642)

For: Soluble Lymphotoxin-Beta Receptors as Therapeutic Agents for  
the Treatment of Systemic Lupus Erythematosus (as amended)

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence, together with all items referred to herein, is being deposited with the United States Post Office as Express Mail Label No. EL543620827US in an Express Mail Envelope addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, DC 20231 on the date shown below.

31 October 2001

Date

Patricia Hofstetter

Patricia Hofstetter

Box Patent Applications  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith is a diskette containing a machine readable copy of the Sequence Listing of the Paper Sequence listing for the above-referenced Patent Application as filed herewith.

The Sequence Listing diskette submitted herewith is the same as the paper form of the Sequence Listing submitted herewith.

Respectfully submitted,

Date: 10-31-01

Niki D. Cox

Niki D. Cox  
Reg. No. 42,446  
BIOGEN, INC.  
14 Cambridge Center  
Cambridge, MA 02142  
(617) 679-2079